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Abstract
We identified three S. cerevisiae lipid elongase null mutants (elo1D, elo2D, and elo3D) that enhance the toxicity of alpha-
synuclein (a-syn). These elongases function in the endoplasmic reticulum (ER) to catalyze the elongation of medium chain
fatty acids to very long chain fatty acids, which is a component of sphingolipids. Without a-syn expression, the various elo
mutants showed no growth defects, no reactive oxygen species (ROS) accumulation, and a modest decrease in survival of
aged cells compared to wild-type cells. With (WT, A53T or E46K) a-syn expression, the various elo mutants exhibited severe
growth defects (although A30P had a negligible effect on growth), ROS accumulation, aberrant protein trafficking, and a
dramatic decrease in survival of aged cells compared to wild-type cells. Inhibitors of ceramide synthesis, myriocin and FB1,
were extremely toxic to wild-type yeast cells expressing (WT, A53T, or E46K) a-syn but much less toxic to cells expressing
A30P. The elongase mutants and ceramide synthesis inhibitors enhance the toxicity of WT a-syn, A53T and E46K, which
transit through the ER, but have a negligible effect on A30P, which does not transit through the ER. Disruption of ceramide-
sphingolipid homeostasis in the ER dramatically enhances the toxicity of a-syn (WT, A53T, and E46K).
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Introduction
Alpha-synuclein (a-syn) is a neuronal protein that has been
linked to Parkinson’s disease (PD) by biochemical and genetic
studies [1]. Alterations in a-syn cause the degeneration of
dopaminergic neurons in an area of the mid-brain called the
substantia nigra pars compacta [2,3]. Loss of these neurons results
in slowness of movement, resting tremor, rigidity, and disturbances
of gait and posture [1,4,5], which are the clinical manifestations of
PD. PD is but one of a group of alpha-synucleinopathies that also
consists of dementia with Lewy bodies, multiple system atrophy
and neurodegeneration with brain iron accumulation type 1.
Human molecular genetic studies have implicated many genes
(ATP13A2, DJ-1, HTRA2, LRRK2, MAPT, Parkin, PINK1, and
UCH-L1) [6,7] other than a-syn [8,9,10,11] that when mutated
produce the constellation of symptoms known as PD. However,
only 10% of all PD cases are due to specific mutations in these
genes, whereas 90% of the cases are ‘‘sporadic’’, meaning there is
no known cause, although a-syn probably is connected to these
cases. Environmental risk factors such as exposure to heavy metals
or pesticides may make a-syn more toxic. This study has used
yeast to identify other potential risk factors that can enhance the
toxicity of a-syn. The unifying concept is that Parkinson’s disease
occurs in some individuals but not others because of an age-related
decrement in the mechanisms that naturally protect cells from
toxic alterations in a-syn.
a-Syn is a small (140 amino acids) protein that constitutes as
much as 1% of the protein in human neurons. a-Syn has been
proposed to regulate cell differentiation, synaptic plasticity and
dopaminergic neurotransmission [12]. A defining feature of a-syn
is its amazing ability to self-associate into an array of soluble and
insoluble high molecular mass species [13], and various post
translation modifications of a-syn can occur (dopamine adduct
formation [14], phosphorylation [15], proteolysis [16], and
nitration [17]) that can alter its aggregation behavior and thus
toxicity. The insoluble b-sheet rich fibers of a-syn that accumulate
in intracytoplasmic deposits, termed Lewy bodies, were once
thought to be the toxic species, but this has fallen out of favor.
Instead, evidence is mounting that the toxic a-syn species is a
soluble high molecular mass protofibril that binds to and pokes
holes in cellular membranes [18]. a-Syn can also cause
proteasome dysfunction [19,20], block endoplasmic reticulum
(ER)-Golgi traffic [21], and inhibit histone acetylation [22], and a-
syn mutants (A30P and A53T) block chaperone-mediated
autophagy [23]. Given these many possibilities, teasing out the
precise mechanism of a-syn toxicity has been challenging.
Genetic screens [21,24,25] have identified many genes that
modify the toxicity of a-syn, but one of the most intriguing findings
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preferentially modify the toxicity of a-syn [24]. In this study we
discovered three lipid elongase genes (ELO1, ELO2, and ELO3)i n
S. cerevisiae that when deleted dramatically increase the toxicity of
(WT, A53T, and E46K) a-syn but not of A30P, resulting in growth
defects, aberrant trafficking, and ROS accumulation. Each of
these elongases is a membrane bound protein that resides in the
endoplasmic reticulum.
Elo1p elongates C14 fatty acids to C16 fatty acids [26]. Elo2p
elongates C16/C18 fatty acids to C22/C24 [27], and Elo3p
elongates C22/C24 fatty acids to C26 fatty acids [27], which are
incorporated into C26-phytoceramide, a component of sphingo-
lipids [28,29]. Null mutations in ELO2 or ELO3 decrease
sphingolipid levels and increase the level of the long chain base
phytosphingosine [27]. Recent reports showed that elo3D cells
cannot synthesize C26-fatty acids and C26-phytoceramide, and
such cells by necessity produce ceramides and sphingolipids that
contain C22 and C24 fatty acids (instead of C26-fatty acids)
[30,31]. The slightly altered ceramide/sphingolipid structure
produces a severe trafficking defect at 37uC in which the essential
plasma membrane H+-ATPase proton pump Pma1p fails to
oligomerize in the ER [32] and fails to traffic to the plasma
membrane [31]; instead, it mistargets to the vacuole. The results in
this report reveal that disruption of the lipid-sphingolipid
homeostasis in the ER dramatically increases the toxicity of a-syn.
Results
The strains and plasmids used in this study are given in Table 1.
A targeted screen of nineteen strains from the yeast deletion
collection in which the genes deleted are involved in lipid
metabolism was conducted (Table 2). Strains were transformed
with a high copy plasmid containing a-syn under control of the gal
promoter, serially diluted on plates with inducing media (+gal),
and scored for growth inhibition compared to the uninduced
condition (-gal). This approach led to the identification of six non-
essential genes that when deleted enhance the toxicity of a-syn
toxicity: ISC1, ELO1, ELO2, ELO3, OSH1, and OSH2. The latter
two genes were recently reported to modify the toxicity of a-syn
[33]. Here, we focused on characterizing the ELO genes that code
for membrane-bound enzymes of the endoplasmic reticulum (ER)
that elongate medium chain fatty acids to C26-VLCFA. Given the
importance of lipid metabolism genes and vesicle trafficking genes
in regulating a-syn toxicity [24], we analyzed the effects of elo
deletions on yeast expressing the various a-syns (WT, A30P,
A53T, and E46K) using a variety of assays.
Null mutations of fatty acid elongase genes enhances the
toxicity of a-syn
The growth of the elo null mutants, with or without WT a-syn,
compared to growth of the wild-type strain (BY4741) is shown
Fig. 1A. Without a-syn expression, the three elo mutants showed
the same growth as the wild-type strain. In contrast, with WT a-
syn expression, each elo mutant grew much slower than the wild-
type strain. The results show that loss of any one of the three
elongase enzymes increases the toxicity of WT a-syn.
The a-syn variants associated with early-onset PD, i.e., A30P,
A53T, and E46K were also tested in the growth assay. The elo1D
strain expressing A53T, E46K, or WT a-syn showed very slow
growth compared to the same cells with empty vector (Fig. 1B);
whereas, elo1D cells expressing A30P grew similar to the same cells
with empty vector. The same pattern was observed for the other
two deletion strains, elo2D and elo3D, in that these two strains
showed a synthetic sick phenotype with A53T, E46K, and WT a-
syn but not with A30P. Western blot analysis demonstrated similar
expression levels for the various a-syns in the various strains
(Fig. 1C); thus, the lack of an effect of A30P is not due to low
expression level. Because the three Elo enzymes are integral
membrane proteins that reside in endoplasmic reticulum, deleting
any one of the three elongase enzymes might preferentially affect
the classical secretory pathway. WT a-syn and A53T [34], and
probably E46K because it associates with the plasma membrane,
transit through the secretory pathway in yeast and mammalian
cells [34,35], whereas, A30P does not. The results show that the
three elongase null mutants exhibit synthetic sick phenotypes with
only those a-syns (WT, A53T, and E46K) that transit through the
secretory pathway.
We also sought to determine whether the elo1D/+a-syn slow
growth phenotype could be rescued by a plasmid carrying wild-
type ELO1 (Fig. 2A). A low-copy plasmid (CEN) carrying wild-type
ELO1 rescued the slow growth phenotype (compare row 5 to rows
2 and 4), whereas a high copy plasmid (2 m) carrying wild-type
ELO1 was lethal (row 6). Over- expression of Elo1p from the high
copy plasmid in elo1D/-a-syn cells was also slightly toxic compared
to wild-type cells (compare row 7 to row 1). To verify that Elo1p
was over- expressed, western blot analysis showed the highest level
of the Elo1p-Tap enzyme in the elo1D strain with the high copy
plasmid, then the elo1D strain with the low copy ELO1 plasmid,
and then the ELO1-TAP integrated strain (with its natural
promoter) (Fig. 2B). Many genes when over-expressed cause
toxicity, and this has been reported for ELO1 [36]. The data
suggests that the toxicity of a-syn exhibits a U-shaped toxicity
curve with respect to Elo1p/palmitate.
We asked whether exogenous medium chain fatty acids could
protect elo1D cells from a-syn. Different length medium chain fatty
acids (from C12 to C18) and phytosphingosine (PHS) were tested
in elo1D cells. The addition of these fatty acids into the medium
caused turbidity; thus, instead of monitoring optical density, which
detects live and dead cells and is affected by turbidity, aliquots of
the culture were removed at the indicated time, diluted, and
spread over plates containing rich media. The number of colony
forming units (CFUs) was obtained in this way.
Yeast media supplemented with medium chain fatty acids at a
low concentration (1 mM) failed to protect the BY4741 wild-type
cells from WT a-syn, whereas at a ten-fold higher concentration
(10 mM) certain fatty acids (C16, C18, and PHS) even increased
WT a-syn toxicity (Table 3). Similar experiments were conducted
on elo1D cells, and for these cells the toxicity of a-syn is readily seen
by the precipitous 90% drop in CFUs upon expression of a-syn:
110 66610
6 cfu/ml (-aS) R 12 68610
6 cfu/ml (+aS) (top row,
Table 3). C16 palmitic acid, C18 stearic acid and PHS at low
concentration (1 mM) partially rescued the toxicity of WT a-syn in
elo1D cells, as judged by the 4-5-fold increase in CFUs, and
increasing the fatty acid concentration failed to give additional
protection. Because Elo1p catalyzes the formation of C16 palmitic
acid, it was expected that palmitic would be beneficial to elo1D
cells, which is what was found.
Enhanced toxicity of a-syn to aged cells
Because PD and other neurodegenerative diseases increase in
frequency with age it is appropriate to explore the relationship
between aging and a-syn toxicity. The chronological lifespan
(CLS, the survival of stationary phase cells over time) assay is one
to way to study aging in yeast [37,38]. The CLS assay was used to
gauge the toxicity of the various a-syns (WT, A30P, A53T and
E46K).
Fig. 3 shows the influence of the different a-syns on the
chronological life span of various yeast strains. Aging curves show
VLCFAs and Alpha-Synuclein Toxicity
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the mean survival time (t50%) is the time to 50% survival. The
aging curves were almost identical for wild-type cells containing
empty vector and expressing A30P (Fig. 3A), i.e., the t50% equaled
12.461.3 d and 10.360.3 d, respectively. In contrast, WT a-syn,
A53T, and E46K were extremely toxic to wild-type cells,
decreasing t50% on average to 3.4 days. The enhanced toxicity
of WT a-syn to aged cells agrees with a previous study [39]. Aging
curves for the various elo cells with and without the different a-syns
are also shown in Fig. 3, and these aging curves exhibited the
following features. First, in experiments using empty vector, each
elongase mutant exhibited decreased mean survival compared to
wild-type cells (t50%=12.461.3 d). Specifically, for elo1D, elo2D
and elo3D cells t50% equaled 8.760.4 d (p=0.022), 6.960.4 d
(p=0.013), and 7.560.5 d (p=0.016) (Fig. 3B–D), respectively.
On average, an elo null mutation produced a 40% decrease in
survival compared to wild-type. Second, WT a-syn, A53T and
E46K (but not A30P) were extremely toxic to the three elongase
Table 1. S. cerevisiae strains and plasmids.
Strain and plasmid Description Source
BY4741 MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
BY4741-ELO1 elo1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
BY4741-ELO2 elo2D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
BY4741-ELO3 elo3D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
BY4741-LAC1 lac1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
BY4741-LAG1 lag1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
SC288C-ISC1 isc1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
BY4741-IFA38 ifa38D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
BY4741-PDR1 pdr1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
SC288C-PDR3 pdr3D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-YDC1 ydc1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-LCB3 lcb3D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-LCB4 lcb4D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-PCT1 pct1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-CWH43 cwh43D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-EEB1 eeb1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-YSR3 ysr3D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-FOX1 fox1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-AYR1 ayr1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
BY4741-SUR2 sur2D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 ATCC
SC288C-OSH1 osh1D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
SC288C-OSH2 osh2D::KanMX MATa his3D1 leu2D0 met15D0 ura3D0 Kelly Tatchell
BY4741-ELO1-TAP TAP-tagged BY4741 at ELO1 C-terminal Open Biosystems
pAG426GAL 2 m URA3 Amp
r GAL1 promoter Addgene
pAG426GAL-EGFP EGFP in pAG426GAL Addgene
pAG415GPD Low copy CEN LEU2 ARS Amp
r GPD1 promoter Addgene
pAG425GAL 2 m LEU2 Amp
r GAL1 promoter Addgene
pAG415GPD-TAP TAP in pAG415GPD Addgene
pAG425GAL-TAP TAP in pAG425GAL Addgene
pAG426GAL-WT WT a-syn in pAG426GAL This study
pAG426GAL-A30P A30P a-syn in pAG426GAL This study
pAG426GAL-A53T A53T a-syn in pAG426GAL This study
pAG426GAL-E46K E46K a-syn in pAG426GAL This study
pAG426GAL-EGFP-WT WT a-syn in pAG426GAL-EGFP This study
pAG415GPD-ELO1 ELO1 in pAG415GPD This study
pAG415GPD-ELO1-TAP ELO1 in pAG415GPD-TAP This study
pAG425GAL-ELO1 ELO1 in pAG425GAL This study
pAG425GAL-ELO1-TAP ELO1 in pAG425GAL-TAP This study
pAG426GAL-EGFP-mts1 EGFP-mts1 in pAG426GAL This study
pAG426GAL-EGFP-mts2 EGFP-mts2 in pAG426GAL This study
doi:10.1371/journal.pone.0015946.t001
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7-8 d R0.5 d) compared to the same cells with empty vector. On
average, a-syn (WT, A53T and E46K) produced a 93% decrease
in the mean survival of each null mutant. Third, the assay revealed
that a-syn is much more toxic to aged elo mutants than to aged
wild-type cells. Specifically, the three a-syns (WT, A53T, and
E46K) that transit through the secretory pathway and bind to the
plasma membrane are extremely toxic to aged elongase mutants,
whereas A30P, which does not use the secretory pathway and is
predominantly cytosolic, is not.
a-Syn can trigger reactive oxygen species (ROS) to accumulate
in the cytosol of human cells and yeast cells and this oxidant
overload may contribute to cell death by apoptosis [40,41]. An
issue is whether ROS accumulates during aging, and for this
purpose the cell permeable dye dihydrorhodamine 123 (DHR
123), which fluoresces only when oxidized, was used. We found
that in the absence of a-syn expression elo cells and wild-type cells
exhibited negligible ROS (,10% of cells stained red) after 24 h
(Fig. 4A). In contrast, elo cells expressing WT a-syn accumulated
appreciable ROS after 24 h compared to the same cells with
empty vector (Fig. 4A), i.e., ,50% versus ,5% of elo cells stained
for ROS with and without WT a-syn expression (Fig. 4B),
respectively. After 48 h, the differences in ROS accumulation
between the aged elo cells with or without a-syn expression were
even more striking. The results show that reactions catalyzed by
the Elo enzymes—the formation of C26 fatty acid and C26-
ceramide—are necessary to suppress a-syn-induced ROS accu-
mulation, and that the rapid decrease in survival in the aged elo
mutants expressing WT a-syn (Figure 3B–C) correlates with the
massive accumulation of ROS induced by a-syn.
If ROS accumulation causes the rapid die-off of aged elo cells
expressing WT a-syn, then an anti-oxidant such as glutathione
(GSH), which effectively eliminates ROS caused by WT a-syn
[41], should inhibit ROS accumulation and prevent the rapid loss
of viability. Figure 4C shows data obtained from 1-d old aged cells
with or without GSH. GSH strongly protected the various aged elo
mutants from WT a-syn, as evidenced by the large ($100%)
increases in survival compared to aged elo cells expressing WT a-
syn without GSH. On the basis of these results, we conclude that
ROS accumulation induced by (WT, A53T or E46K) a-syn causes
the rapid die-off of aged cells, particularly aged elo cells.
To determine whether the elo null mutations perturb the
localization of WT a-syn, fluorescence microscopy was conducted
using a green fluorescent variant of WT a-syn (EGFP-WT-a-syn)
after a 6 h induction. In wild-type cells, EGFP-WT-a-syn
primarily localized to the plasma membrane (Fig. 5); whereas, in
elo1D cells, EGFP-WT-a-syn accumulated in multiple cytosolic
inclusions or vesicles per cell, and, in general, less plasma
membrane binding occurred. Similar results were obtained for
elo2D and elo3D cells. EGFP showed the same diffuse cytoplasmic
localization in the various strains. Loss of the various Elo enzymes
clearly affects the localization of a-syn, and the altered localization
might underlie the enhanced toxicity of a-syn these strains.
Cells expressing a-syn (WT, A53T or E46K) are sensitive to
fumonisin B1 (FB1) and myriocin
The elongase enzymes Elo2p and Elo3p are required for the
synthesis of C26-fatty acids, which is a component of ceramides
and sphingolipids, and loss of either of these two enzymes results in
ceramides that contain fatty acids other than the required C26 FA
[31,32]. In yeast, two enzymes, Lag1p and Lac1p, synthesize
ceramides [42,43,44]. We tested lag1D and lac1D strains for
sensitivity to a-syn but found no effect (Table 2). We also tested a
lag1Dlac1D double deletion strain for sensitivity to a-syn, but had
difficulty growing the strain in galactose; thus, it could not be
determined whether elimination of ceramide synthase activity
increased a-syn toxicity. As an alternative approach, we depleted
cells of ceramide using FB1 [45] to inhibit ceramide synthase or
myriocin to inhibit serine palmitoyltransferase (SPT) [46].
The growth properties of BY4741 cells transformed with vector
control or various a-syns (WT, A30P, A53T or E46K) and with
FB1 (5 mM) or myriocin (1 mM) added to the galactose plates is
shown in Fig. 6A. FB1 and myriocin were extremely toxic to cells
expressing WT a-syn, A53T or E46K compared to vector control
cells, but much less toxic to cells expressing A30P. Each compound
also slowed the growth of the cells with empty vector, but the
effects were far more pronounced in the cells that expressed the a-
syns that transit through the secretory pathway.
Fluorescence microscopy revealed the effects of the two
inhibitors on the localization of EGFP-WT-a-syn in wild-type
cells. In cells without added drugs, EGFP-WT-a-syn was clearly
enriched in the plasma membrane (Fig. 6B), whereas EGFP was
distributed through out the cells. In cells expressing GFP-WT-a-
syn and treated with FB1 the GFP-WT-a-syn protein was nearly
absent from the plasma membrane; instead, the protein localized
in cytosolic inclusions, vesicles, or a cellular compartment. Similar
images were obtained for cells expressing GFP-WT-a-syn and
treated with myriocin. Both drugs failed to affect the localization of
EGFP. The results indicate that cells that fail to synthesize
ceramides have defects in the trafficking of a-syn.
Table 2. Analysis of the growth of wild-type (BY4741) and
deletion mutants with or without WT a-syn.
Growth
b
Strain
a 2 a-syn + a-syn
WT +++ ++
lac1D +++ ++
lag1D +++ ++
isc1D +++ +
ifa38D +++ ++
ydc1D +++ ++
lcb3D +++ ++
lcb4D +++ ++
elo1D +++ +
elo2D +++ +
elo3D +++ +
pct1D +++ ++
cwh43D +++ ++
eeb1D +++ ++
ysr3D +++ ++
fox1D +++ ++
ayr1D +++ ++
sur2D +++ ++
osh1D +++ +
osh2D +++ +
aStrains deleted for these genes are listed in Table 1.
bStrains harboring empty vector or WT a-syn were spotted onto SC-galactose
medium. Growth was scored on a scale from +++ . ++ . + after 3 days at
30uC.
doi:10.1371/journal.pone.0015946.t002
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a-syn, to elo3D cells
To probe protein trafficking to the plasma membrane in elo
cells, two different variants of EGFP that contain a short C-
terminal plasma membrane-targeting sequence were constructed:
EGFP-mts1 (mts1, SNSVCCTLM) contains a short C-terminal
membrane targeting sequence derived from Ste18 protein, and
EGFP-mts2 (mts2, GSGGCCIIS) contains a similar C-terminal
sequence derived from Ras2 [47]. Ste18 traffics through the ER to
the plasma membrane whereas Ras2 may use an alternative
pathway en route to the plasma membrane. Targeting a non-toxic,
universally used protein like EGFP to the plasma membrane (by
whatever route) could give insight into the molecular defects in
elo3D cells. Below, wild-type cells expressing the different EGFP
variants (with or without added FB1) are compared to elo3D cells
expressing the different EGFP variants.
The growth properties of cells expressing EGFP-mts(1,2) or
EGFP are shown in Fig. 7A. EGFP-mts(1,2) and EGFP were not
toxic to wild-type cells, as judged by the lack of growth defects
compared to vector control cells. However, when the same cells
were treated with FB1 (5 mM) severe growth defects occurred for
cells expressing EGFP-mts(1,2) but not for cells expressing EGFP.
Inhibiting ceramide synthesis clearly had a much bigger effect on
cells expressing the mts-tagged EGFP molecules. Growth proper-
ties of elo3D cells expressing EGFP-mts(1,2) or EGFP were also
conducted. In this mutant, which synthesizes C24-ceramides
rather than C26-ceramides [31,32], slight but reproducible growth
defects occurred for cells expressing the mts-tagged EGFP
molecules. The data show that inhibiting ceramide synthesis or
synthesizing ceramides with slightly shorter fatty acid chains
produces growth defects in cells that express EGFP with a plasma
membrane targeting sequence.
Fluorescence microscopy was conducted to assess the effects of
FB1 and elo3D on EGFP (6 mts tag) localization (Fig. 7B). The
EGFP-mts1 protein localized to the plasma membrane, as
expected, whereas the untagged variant was distributed through
out cells. The same cells treated with FB1 had much less
membrane bound EGFP-mts1; instead, the protein was clustered
in the cytosol in inclusions, vesicles, or in some cellular
compartment. Similar results were obtained for cells expressing
EGFP-mts2. Note that elo3D cells expressing EGFP-mts(1,2) also
had much less EGFP-mts(1,2) on the plasma membrane than wild-
type cells, and overall, in this mutant the membrane-tagged EGFP
molecules sequestered in the cytosol in inclusions, vesicles, or in
some cellular compartment. Inhibiting ceramide synthesis or
slightly altering the length of the fatty acid chain has dramatic
Figure 1. Enhanced a-syn toxicity in elongase null mutants. (A) The effect of WT a-syn expression on the growth of three deletion strains
(elo1D, elo2D, and elo3D) and the wild-type BY4741 strain was evaluated. In panels (A, B), strains were transformed with pAG426GAL-WT (WT a-syn),
pAG426GAL-A30P (A30P), pAG426GAL-A53T (A53T), pAG426GAL-E46K (E46K) or pAG426GAL (empty vector) and spotted in successive 10-fold serial
dilutions on solid sucrose and solid galactose plates and incubated for 3 days at 30uC. Experiments were repeated three times with similar results. (B)
The effect of the various a-syns (WT, A30P, A53T, or E46K) on the growth of the three elo deletion strains was also evaluated. (C) Western blot analysis
of yeast cells expressing a-syn. Lysates were prepared from cultures grown for 6 h in inducing medium and then subjected to SDS–PAGE followed by
western blot analysis. The cell-signaling polyclonal antibody against a-syn was used to visualize the three a-syns. The loading control was the yeast
protein Pgk1p. Identical amounts of protein were loaded per well. Plasmids: see panel (A).
doi:10.1371/journal.pone.0015946.g001
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cell.
Discussion
We have shown that the elo mutations and ceramide synthesis
inhibitors dramatically enhance the toxicity of those a-syn variants
that use the classical secretory pathway, i.e., WT, A53T, and
E46K a-syn. Whereas, A30P, which does not use the classical
secretory pathway, was unaffected by such mutations and
inhibitors. Overall, this study shows that disruption of lipid
homeostasis in the ER converts WT a-syn from a relatively non-
toxic protein into a toxic one. Humans possess six Elo genes
(ELOVLs) [48], and these genes are gaining attention because of
their roles in diabetes [49], macular degeneration [50], cancer
[51], and the production of long chain polyunsaturated fatty acids
[52].
Enhanced a-syn toxicity in elo1D
The elo1D mutant has the same lipid profile as wild-type cells
[26], but, in nearly all our assays, the elo1D mutant and wild-type
cells were different (Figs. 1, 2, 3, 4, 5). One possibility is that a
different distribution of lipids occurs in the two strains because
Elo1p and FAS carry out the same reaction (C14 fatty acidR C16
fatty acid) but in different compartments. To compensate for the
loss of Elo1p activity, palmitoyl-CoA must transfer from the
cytosol into the ER, and if this transfer is inefficient mutant cells
will have a sub-optimal concentration of this important lipid in the
ER (and excess in the cytosol). The defects associated with elo1D
cells observed in this study could be due to a deficit of palmitoyl-
CoA in the ER compared to wild-type cells. Furthermore, because
the ER is the compartment where proteins are palmitoylated, a
process that requires palmitoyl-CoA, perhaps elo1D cells are
defective in protein palmitoylation. We propose that a-syn (WT,
A53T, or E46K) is more toxic to elo1D cells than to wild-type cells
because elo1D cells expressing a-syn probably have two ER defects,
i.e., one from the loss of palmitate and the other because a-syn
inhibits ER to Golgi traffic [21]. WT a-syn is even more toxic to
aged elo1D cells as evidenced by massive ROS accumulation
(Figs. 3, 4).
Depending on the concentration, exogenous palmitate (C16)
was helpful or harmful to wild-type and elo1D cells expressing WT
a-syn (Table 3). In general, 10 mM palmitic acid was toxic to wild-
type and elo1D cells expressing WT a-syn compared to 1 mM
palmitic acid. Over-expressing Elop1 from a 2 m plasmid was also
very toxic to cells expressing WT a-syn (Fig. 2B), which indicates
that elevated palmitic acid enhances a-syn toxicity. Note that
prolonged exposure of a-syn to the lipid docosahexaenoic acid,
which occurs at high levels in the brain, induces a-syn to form
amyloid fibers [53]. Based on our findings, we propose that the
toxicity of WT a-syn exhibits a U-shaped toxicity profile against
palmitate and other lipids/sphingolipids.
Sphingolipid metabolism defects in elo2D and elo3D cells
Biochemical analysis of lipid extracts from the elo2D and elo3D
mutants have shown that these mutants fail to synthesize VLCFAs
and have defects in sphingolipid metabolism [27,54]. In the case of
elo3D, cells fail to synthesize C26 VLCFA and C26-phytocer-
amide, instead they synthesize C22- and C24- forms of
phytoceramide [54]. Aged elo2D and elo3D mutants exhibited a
modest, but significant, decrease in survival compared to aged
wild-type cells, although neither mutant accumulated significant
levels of ROS (Figs. 3, 4). a-Syn was extremely toxic to aged elo2D
and elo3D cells compared to aged wild-type cells. Specifically, a-
syn triggered massive ROS accumulation, which triggers the
Figure 2. elo1D/+a-syn slow growth phenotype is rescued by
ELO1. (A) Growth properties of wild-type cells and elo1D cells
expressing WT a-syn (pAG426GAL-WT) and expressing Elo1p from a
CEN plasmid (pAG415GPD-ELO1) or over expressing from a 2 m plasmid
(pAG425GAL-ELO1 are shown. The spot assay was conducted as
described in Fig. 1. (B) The western blot analysis shows the level of
Elo1p-Tap protein in ELO1-TAP cells, in elo1D cells transformed with
pAG415GPD-ELO1 (CEN, GPD1 promoter), and in elo1D cells trans-
formed with pAG425GAL-ELO1 (2 m, GAL1 promoter). A monoclonal
antibody against the tap tag was used, and Pgk1 was used as the
loading control.
doi:10.1371/journal.pone.0015946.g002
Table 3. Analysis of exogenous fatty acids on the growth of
wild-type cells and elo1D cells with or without WT a-syn.
WT (cfu 610
6/ml) elo1D (cfu 610
6/ml)
compound vector WT a-syn vector WT a-syn
(2) 126614 74613 110616 1268
12:0 (1 mM) 126614 73691 1 5 681 5 610
12:0 (10 mM) 112610 58681 0 5 699 63
16:0 (1 mM) 124612 80616 120685 6 69
16:0 (10 mM) 104611 21611 119610 2065
18:0 (1 mM) 123698 1 610 120676 4 67
18:0 (10 mM) 102672 8 661 0 7 612 1766
PHS (10 mM) 128697 0 651 1 8 613 5868
PHS (20 mM) 82662 2 699 3 683 0 67
SC-galactose liquid media supplemented fatty acids was inoculated with 1610
5
cells/ml, incubated for 24 hr at 30uC, and then CFU assay was carried out. The
assay was conducted three times.
Abbreviations, 12:0; lauric acid, 16:0; palmitic acid, 18:0; stearic acid, PHS;
phytosphingosine.
doi:10.1371/journal.pone.0015946.t003
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membrane-targeting forms of EGFP were even slightly toxic to
elo3D cells (Fig. 7). The elo3D mutant is known to cause the
aberrant trafficking of the essential plasma membrane proton
pump protein Pma1 [32]. For example, instead of transiting
through the ER to the plasma membrane Pma1 targets to the
vacuole for degradation in elo3D cells. We propose that the elo2D
and elo3D mutants have subtly altered ceramide/sphingolipid
homeostasis that in turn triggers protein trafficking defects in the
ER. Expressing a-syn in these mutant cells, especially aged cells,
exacerbates these trafficking defects and leads to aberrant a-syn
trafficking, ROS accumulation and cell death.
Inhibition of ceramide synthesis
Fumonisin B1 is an environmental toxin synthesized by various
fungi that infest maize (corn) worldwide (see: www.inchem.org/
documents/ehc/ehc/ehc219.htm). Pregnant woman who con-
sume FB1-infested corn show a higher incidence of children born
with neural tube defects [55,56]. Consumed at high levels over a
long period of time (perhaps decades) FB1 may produce
neuropathological effects in humans. The point is that this toxin
can alter a-syn trafficking and boost its toxicity, as shown herein.
Fumonisin B1 and myriocin were extremely toxic to cells
expressing WT, A53T or E46K a-syn but much less toxic to cells
expressing A30P (Fig. 6A). These drugs were also extremely toxic
to cells expressing membrane-targeting forms of EGFP but not
soluble EGFP (Fig. 7A). Both drugs appeared to prevent the
trafficking of WT a-syn (and EGFP-mts) to the plasma membrane
(Figs. 6B, 7B). Our interpretation of these findings is that these two
drugs disrupt the ceramide-sphingolipid homeostasis in the ER
and this causes aberrant trafficking of proteins that transit through
the ER like WT, A53T or E46K a-syn. The combination of a-syn
aberrant trafficking, a-syn inclusion formation and ROS accumu-
lation kills cells.
Given our findings of the sensitivity of a-syn trafficking to the
proper lipid homeostasis in the ER, we ask whether a decrease in
VLCFA or sphingolipid levels might occur with age in some
people, and whether such a condition might predispose one to PD.
Figure 3. a-Syn is extremely toxic to aged cells. (A) This panel shows chronological aging curves for wild-type BY4741 cells with empty vector
(closed square), WT a-syn (closed circle), A30P (open triangle), A53T (inverted open triangle), or E46K (gray diamond). The various cells were grown in
selective media containing sucrose to stationary phase, and then the cells were washed and resuspended in selective media containing galactose.
After two days of further incubation, the aging analysis started. At the indicated times aliquots were removed form the culture, diluted onto plates
containing rich media, incubated for 2 days, and then colonies were counted. Curves represent the number of colonies at the given time divided by
the number of colonies at time zero. Experiments were conducted three times, and error bars represent 6 s.e.m. P-values are given in the text.
Plasmids used: pAG426GAL (empty vector), pAG426GAL-WT (WT a-syn), pAG426GAL-A30P (A30P), pAG426GAL-A53T (A53T), and pAG426GAL-E46K
(E46K). (B), (C) and (D) show chronological aging curves for elo1D, elo2D, and elo3D mutants, respectively, with the various a-syns.
doi:10.1371/journal.pone.0015946.g003
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showed that serum levels of sphingomyelins (SM) and ceramide
may be good pre-clinical biomarker of memory impairment like
that associated with the long preclinical stage of Alzheimer’s
disease [57]. In short, it is reasonable to investigate whether a low
level of VLCFAs or ceramide is a risk factor for PD. If so, these
compounds could serve as biomarkers for PD.
Materials and Methods
Yeast strains, media, and transformation
The primary yeast strains used in this study were BY4741
(American Type Culture Collection; ATCC, Manassas, VA), and
BY4741-ELO1-TAP (Open Biosystems), which contains an
integrated copy of ELO1-TAP replacing the WT allele (Table 1).
Deletion strains derived from haploid yeast BY4741 and S288C
were purchased from ATCC or were a gift from Kelly Tatchell
(LSUHSC, Shreveport, LA), respectively. Rich medium consisted
of 1% yeast extract, 2% peptone, and 2% glucose (YPD). Synthetic
complete (SC) medium consisted of 0.67% yeast nitrogen base,
0.16% yeast drop-out mix (Sigma-Aldrich, St-Louis, MO), and
carbon sources (2% glucose, sucrose, or galactose). Plates
contained 2% agar (Difco, Detroit, MI). Transformation of yeast
strains was performed by the lithium acetate method [58]. Cells
transformed with various plasmids were pre-grown in SC-glucose
drop out media to maintain selection for plasmids. Typically, in
the various experiments, cells harboring the plasmid of interest
were pre-grown until mid-log phase in SC-sucrose drop out media
(non-inducing media) and then centrifuged, washed and resus-
pended in SC-galactose drop out media (inducing media). In some
cases, media was supplemented with fatty acids, i.e., 0.5% Brij 58
and C12:0, C16:0, or C18:0 fatty acids (Sigma) at concentrations
of 1 mM or 10 mM. Phytosphingosine (PHS) was dissolved in
ethanol (at 10 mM) and added to sterilized culture media to yield
Figure 4. a-Syn triggers ROS in aged elo cells. (A) Wild-type cells containing empty plasmid (pAG426GAL) or expressing WT a-syn (pAG426GAL-
WT) were cultured for 24 h in inducing media (+gal) at 30uC. After 24 h, cells were incubated with DHR 123 (5 mg/ml) for 1 h, and then visualized by
differential interference contrast (DIC) and fluorescence microscopy (DHR). Cells were counted and the percentage of cells exhibiting red fluorescence
was plotted. (B) Plot of the percentage of cells (WT, elo1D, elo2D, and elo3D) that exhibited red fluorescence due to ROS accumulation. Cultures were
grown for 24 h in inducing media at 30uC and then stained with DHR. Each value was obtained from two independent experiments, where the total
number of cells counted was 600. Error bars reflect s.e.m. (C) Reduced glutathione (GSH) protects aged cells from WT a-syn. The various cells
expressing WT a-syn were grown in selective media containing sucrose to stationary phase, and then cells were washed and resuspended in
galactose media with or without 10 mM GSH. After 3 days (1 day on aging curve) incubation, aliquots were removed from culture, diluted onto plates
containing rich media, incubated for 2 days, and then colonies were counted. Each bar represents the number of colonies at the 3 days divided by the
number of colonies at time zero. Experiments were conducted three times, and error bars represent 6 s.e.m.
doi:10.1371/journal.pone.0015946.g004
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or EGFP were cultured in inducing media for 6 h at 30uC and then visualized by fluorescence microscopy. Plasmids: pAG426GAL-EGFP-WT-a-syn and
pAG426GAL-EGFP.
doi:10.1371/journal.pone.0015946.g005
Figure 6. Hypersensitivity of cells expressing a-syn (WT, A53T or E46K) to fumonisin B1 (FB1) and myriocin. (A) The toxicity of FB1 and
myriocin was evaluated by evaluating the growth properties of various cells in a serial dilution assay. Strains were transformed with empty vector or
plasmids harboring the various a-syns (WT a-syn, A30P, A53T, or E46K) and spotted in successive 10-fold serial dilutions on solid sucrose and solid
galactose plates and incubated for 3 days at 30uC. FB1 and myriocin were dissolved in the media at 5 mMo r1mM, respectively. Experiments were
repeated three times with similar results. The pAG426GAL set of plasmids were used. (B) FB1 and myriocin drives WT a-syn off the plasma membrane
and into inclusions. Wild-type cells expressing eGFP-WT-a-syn or eGFP were incubated for 6 h in inducing media containing 5 mM FB1 or 1 mM
myriocin or drug vehicle, ethanol (2)a t3 0 uC. Images were obtained by fluorescence microscopy 6 h after adding myriocin. Approximately 85%, and
80% of the cells examined exhibited the EGFP-WT-a-syn inclusions as shown in the upper center (+Fum) and right panel (+Myr), respectively.
Plasmids: pAG426GAL-EGFP-WT-a-syn and pAG426GAL-EGFP.
doi:10.1371/journal.pone.0015946.g006
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used as a 2.5 mM stock solution in ethanol and added to sterilized
media to a final concentration of 1 or 5 mM.
Plasmid construction
The plasmids used in this study are listed in Table 1. Plasmids
were constructed using the in vitro recombination-based Gateway
cloning system (Invitrogen, Carlsbad, CA) (as described in [59]).
The coding sequence of a-syn (WT, A30P, A53T, or E46K) (from
template plasmids [41]) and ELO1 (from BY4741 genomic DNA)
was amplified by PCR with forward and reverse primers that
contained a 25-nucleotide (nt) attB sequence and 25-30 nt of the
complementary gene-specific sequence. Purified double-stranded
PCR products were then recombined with the counter-selectable
ccdB gene of the donor vector pDONR221 using the BP clonase
enzyme mixture. The donor vector containing the gene of interest
was then cloned into the Gateway destination vectors pAG426-
GAL, pAG426GAL-GFP, pAG415GPD, pAG415GPD-TAP,
pAG425GAL, or pAG425GAL-TAP (Addgene, Cambridge,
MA) using the LR clonase enzyme mixture. The pDONR221
donor vector is commercially available (Invitrogen).
The EGFP-plasma membrane targeting sequence of Ste18p (GFP-
mts1) and EGFP-plasma membrane targeting sequence of Ras2p
(GFP-mts2) constructs were also prepared using the recombination-
based Gateway cloning system. The EGFP inserts from a template
plasmid were PCR amplified using the forward primer 5’-GGGGA-
CAAGTTTGTACA-AAAAAGCAGGCTTCGAAGGAGATAGA-
ACCATGAGTAAAGGAGAAGAACTTTTCACTG-39, which
contains the attB1 sequence and a sequence complementary to the
DNA coding for EGFP, and the reverse primers 59-GGGGAC-
CACTTTGTACAAGAAAGCTGGGTCCTACATAAGCGTAC-
AACAAACAC TATTTGATTTGTATAGTTCATCCATGCC-
ATGTG-39; which contains the attB2 sequence and a sequence that
codes for the plasma membrane targeting sequence (mts1 protein
sequence: SNSVCCTLM) and 59-GGGGACCACTTTGTACAA-
GAAAGCTGGGTCCTAACTTATAATACAACAGCCACCCG-
ATCCTTTGTATAGTTCATCCATGCCATGTG-39,w h i c hc o n -
tains the attB2 sequence and a sequence that codes for the plasma
membrane targeting sequences(mts2protein sequence:GSGGCCIIS),
respectively. The purified double-stranded PCR products were
transferred into the Gateway destination vector pAG426GAL yielding
pAG426GAL-EGFP-mts1 and pAG426GAL-EGFP-mts2 in the
sequence of steps described above, respectively.
Growth and CFU assay
For analysis of growth by plate assays, yeast cells grown in 3 ml
of SC-sucrose media in 16-mm sterilized tubes with plastic cap for
overnight (15 h) at 30uC were harvested by centrifuge (70006g)
for 10 minutes at room temperature, washed with phosphate
buffered-saline (PBS), and resuspended in the same buffer to a
concentration of 1.0610
8 cells ml
-1. After the cell suspensions were
serially diluted in 10-fold steps, a 5 ml aliquot of each dilution was
spotted onto SC-sucrose (-gal) and SC-galactose (+gal) plates, and
the plates were then incubated for 3 days at 30uC.
For growth assay in the liquid medium, colony forming units
(CFU) assay was performed. Aliquots of the washed cell suspension
Figure 7. A plasma membrane-binding form of EGFP is toxic, like a-syn, to elo3D cells. (A) Inhibiting ceramide synthetase with FB1, serine
palmitoyltransferase with myriocin or blocking C26-VLCFA synthesis in elo3D cells drives EGFP-mts1 and EGFP-mts2 into cytoplasmic inclusions. Wild-
type cells or elo3D cells expressing EGFP-mts1, EGFP-mts2 or EGFP as a control were incubated for 6 h in inducing media containing 5 mM FB1, 1 mM
myriocin (or drug vehicle, ethanol) and then imaged by fluorescence microscopy. Approximately 80%, 68%, and 88% of the cells examined exhibited
the EGFP-mts1 inclusions as shown in the wild-type strain (+Fum), (+Myr), and in the elo3D strain, respectively. 85%, 75%, 70% of the cells examined
exhibited the EGFP-mts2 inclusion as shown in the wild-type strain (+Fum), (+Myr), and in the elo3D strain, respectively. Plasmids: pAG426GAL-EGFP-
mts1, pAG426GAL-EGFP-mts2, and pAG426GAL-EGFP. (B) Growth properties of cells expressing EGFP-mts1, EGFP-mts2, or EGFP were evaluated in a
dilution spot assay. EGFP-mts1 or EGFP-mts2 is not toxic to wild-type cells, whereas it was very toxic to FB1-treated (5 mM) wild-type cells and to
elo3D cells. The control construct EGFP was not toxic to any of the cells. The assay was conducted according to the legend in Fig. 1.
doi:10.1371/journal.pone.0015946.g007
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long chain base (PHS) media at final concentration of 1.0610
5
cells ml
-1.1 0ml aliquots of the 5 ml cultures were removed at the
indicated time-points, diluted in sterile PBS buffer, spread onto at
least three YPD plates (maximum colony ,500 colonies per plate),
and allowed to grow into colonies for 3 days. The colonies were
then counted.
Chronological life span assay
Chronological aging experiments were performed as described
[60,61]. Yeast cells were inoculated into 5 ml of SC-sucrose media
in 18-mm glass culture tubes with plastic caps. These starter
cultures were grown overnight on a rotating roller drum (model
TC-7; New Brunswick Scientific, Edison, NJ, USA) such that the
tubes were vertically tilted ,15u from horizontal and rotating at
,50 rpm to maintain the cells in suspension. The roller drum was
positioned within an incubator set at 30uC. One hundred
microliters of the overnight culture was then inoculated into
5 ml SC-galactose media and incubated on the roller drum for the
duration of the experiment, except for brief times that cultures
were removed for plating of aliquots. Forty-eight hours later was
considered as the zero time-point (day 0). Cell viability on aging
was measured by CFU assay as listed above.
Western blot analysis
Western blots were conducted as described [41], with minor
modification. In brief, yeast cells transformed with plasmids with
a-syn (pAG426GAL-WT, A30P, A53T, or E46K) and Elo1p-TAP
(pAG415GPD-ELO1-TAP or pAG425GAL-ELO1-TAP) or the
Open Biosystems ELO1-TAP-tagged integrated strain were
cultured in SC-sucrose media to mid-log phase and then shifted
into SC-galactose media for 6 h at 30uC. Cells were lysed (and all
subsequent manipulations were carried out at ice temperature), a
protease inhibitor cocktail (Roche) was added, and then the
protein concentration was determined (Bio-Rad protein assay).
Samples (80 mg/well) were subjected to SDS-PAGE and then
transferred to a nitrocellulose membrane for detection of a-syn
and TAP. The monoclonal antibody against human a-syn was
purchased from Cell Signaling Technologies (#2642). The
monoclonal antibody against Pgk1p was purchased from Invitro-
gen. The polyclonal antibody against TAP was purchased from
Open Biosystems. Secondary antibodies were purchased from
Santa Cruz Biotechnology. Chemoluminescence detection (GE
Health Care) was used to visualize a-syn, TAP, and Pgk1p.
Western blot analysis was repeated three times.
Fluorescence microscopy
Fluorescence microscopy was performed with an Olympus
AX70 microscope, equipped with an Olympus UPlanFI 1006/
1.35 NA objective and a Roper CoolSNAP HQ CCD camera.
The acquisition software was IPLab v.3.6 from Scanalytics Inc.
Chroma 41001 (HQ 480/40 exciter, HQ 535/50 emitter, Q 505
LP dichroic) filter set was used for detecting EGFP. Data were
collected at room temperature. The ROS assay, using the DHR
123 dye, was performed as described previously [41]. Aged cells
for 1 d were stained with DHR 123 (5 mg/ml) for 1 h at 30uC.
Error analysis
The t50 values from the various elo (6 a-syn) aging curves were
compared to control curves with a paired Student’s t-test using
EXCEL.
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